Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.40
EXEL's Cash to Debt is ranked higher than
50% of the 1443 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. EXEL: 0.40 )
EXEL' s 10-Year Cash to Debt Range
Min: 0.4   Max: No Debt
Current: 0.4

Equity to Asset -0.35
EXEL's Equity to Asset is ranked lower than
52% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. EXEL: -0.35 )
EXEL' s 10-Year Equity to Asset Range
Min: -3.9   Max: 0.79
Current: -0.35

-3.9
0.79
F-Score: 2
Z-Score: -8.98
M-Score: -2.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -893.86
EXEL's Operating margin (%) is ranked higher than
57% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -95.34 vs. EXEL: -893.86 )
EXEL' s 10-Year Operating margin (%) Range
Min: -893.86   Max: 30.91
Current: -893.86

-893.86
30.91
Net-margin (%) -1069.42
EXEL's Net-margin (%) is ranked higher than
56% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -77.05 vs. EXEL: -1069.42 )
EXEL' s 10-Year Net-margin (%) Range
Min: -1069.42   Max: 26.14
Current: -1069.42

-1069.42
26.14
ROA (%) -62.36
EXEL's ROA (%) is ranked higher than
57% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. EXEL: -62.36 )
EXEL' s 10-Year ROA (%) Range
Min: -134.14   Max: 20.08
Current: -62.36

-134.14
20.08
ROC (Joel Greenblatt) (%) -5904.61
EXEL's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 1411 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. EXEL: -5904.61 )
EXEL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6114.36   Max: 736.4
Current: -5904.61

-6114.36
736.4
Revenue Growth (3Y)(%) -61.20
EXEL's Revenue Growth (3Y)(%) is ranked higher than
57% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. EXEL: -61.20 )
EXEL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -61.2   Max: 25.6
Current: -61.2

-61.2
25.6
» EXEL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

EXEL Guru Trades in Q1 2014

Louis Moore Bacon 250,000 sh (New)
Paul Tudor Jones 15,713 sh (New)
Steven Cohen 17,977 sh (+25.71%)
Jean-Marie Eveillard 400,000 sh (-65.91%)
» More
Q2 2014

EXEL Guru Trades in Q2 2014

Jim Simons 1,658,150 sh (New)
Jean-Marie Eveillard Sold Out
Paul Tudor Jones Sold Out
Louis Moore Bacon Sold Out
» More
Q3 2014

EXEL Guru Trades in Q3 2014

Paul Tudor Jones 28,200 sh (New)
Jim Simons Sold Out
» More
Q4 2014

EXEL Guru Trades in Q4 2014

Jim Simons 178,033 sh (New)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with EXEL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 23.83
EXEL's P/S is ranked higher than
66% of the 1611 Companies
in the Global Biotechnology industry.

( Industry Median: 37.64 vs. EXEL: 23.83 )
EXEL' s 10-Year P/S Range
Min: 1.65   Max: 50.5
Current: 23.83

1.65
50.5
Current Ratio 0.97
EXEL's Current Ratio is ranked higher than
50% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.39 vs. EXEL: 0.97 )
EXEL' s 10-Year Current Ratio Range
Min: 0.92   Max: 5.81
Current: 0.97

0.92
5.81
Quick Ratio 0.96
EXEL's Quick Ratio is ranked higher than
52% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. EXEL: 0.96 )
EXEL' s 10-Year Quick Ratio Range
Min: 0.92   Max: 5.81
Current: 0.96

0.92
5.81
Days Inventory 530.94
EXEL's Days Inventory is ranked higher than
76% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EXEL: 530.94 )
EXEL' s 10-Year Days Inventory Range
Min: 35.45   Max: 471.76
Current: 530.94

35.45
471.76
Days Sales Outstanding 70.96
EXEL's Days Sales Outstanding is ranked higher than
81% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 139.31 vs. EXEL: 70.96 )
EXEL' s 10-Year Days Sales Outstanding Range
Min: 4.51   Max: 82.11
Current: 70.96

4.51
82.11

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 3.00
EXEL's Price/Median PS Value is ranked higher than
70% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. EXEL: 3.00 )
EXEL' s 10-Year Price/Median PS Value Range
Min: 0.27   Max: 4.83
Current: 3

0.27
4.83
Earnings Yield (Greenblatt) -27.70
EXEL's Earnings Yield (Greenblatt) is ranked lower than
59% of the 1398 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. EXEL: -27.70 )
EXEL' s 10-Year Earnings Yield (Greenblatt) Range
Min: -27.7   Max: 16.4
Current: -27.7

-27.7
16.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:EX9.Germany,
Exelixis Inc incorporated in November, 1994. It is a biotechnology company which develops small molecule therapies to treat cancer. Its two advanced assets, COMETRIQ "cabozantinib", its wholly-owned inhibitor of multiple receptor tyrosine kinases, and cobimetinib "GDC-0973/XL518", a potent, highly selective inhibitor of MEK, which it out-licensed to Genentech, Inc. a wholly-owned member of the Roche Group, or Genentech, are currently the subject of six ongoing phase 3 pivotal trials. Cabozantinib is being evaluated in a development program, including two ongoing phase 3 pivotal trials in metastatic castration-resistant prostate cancer or CRPC, an ongoing phase 3 pivotal trial in metastatic renal cell cancer or RCC, and an ongoing phase 3 pivotal trial in advanced hepatocellular cancer, or HCC. The programs that the Company runs are Cabozantinib Development Program, CRPC, COMET Pivotal Trials, Combination trials. The Company has development programs in collaboration with Genentech, GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, Daiichi Sankyo Company Limited. It contracts third parties to manufacture raw materials, the active pharmaceutical ingredient, or API, and finished solid dose COMETRIQ products for clinical and commercial uses. The Company follows regulations set forth by FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries. Federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, are applicable to the Company.
» More Articles for EXEL

Headlines

Articles On GuruFocus.com
5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic Communications Inc, and Aeropostale I Dec 28 2014 
5-year lows: National Presto Industries, Ennis Inc, Landauer Inc, and Exelixis Inc. Sep 28 2014 
Weekly 3-Year Low Highlights: UAN, CLD, EXEL, QNST Sep 06 2014 
Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian Trust, Millennial Media Inc., Exelix May 05 2014 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Exelixis Inc. Reports Operating Results (10-K) Feb 22 2011 
Exelixis Inc. (EXEL) CFO Frank Karbe buys 16,500 Shares Aug 25 2010 
Exelixis Inc. Reports Operating Results (10-Q) Aug 05 2010 
Exelixis Inc. Reports Operating Results (10-Q) May 11 2010 
Exelixis Announces Second Quarter 2009 Financial Results Jul 30 2009 


More From Other Websites
Biotech Investors: May 29th Could Be A Big Day Apr 21 2015
Exelixis (EXEL) Shares March Higher, Can It Continue? - Tale of the Tape Apr 20 2015
The Zacks Analyst Blog Highlights: Rigel Pharmaceuticals, Exelixis and Atlas Resource Partners -... Apr 20 2015
Why Exelixis (EXEL) Stock Might be a Great Pick - Tale of the Tape Apr 20 2015
3 Momentum Picks Under $10 to Sail the Turbulent Market - Analyst Blog Apr 17 2015
Exelexis (EXEL) Is The 'Chart of the Day' Apr 16 2015
Bulls can't get enough of Exelixis Apr 13 2015
Exelixis' Cometriq Gets Fast Track Status in U.S. - Analyst Blog Apr 10 2015
Exelixis to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015 Apr 09 2015
Exelixis to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015 Apr 09 2015
Exelixis (EXEL) Stock Rises Today Following FDA Fast Track Designation Apr 09 2015
Exelixis’ Cabozantinib Granted Fast Track Designation by FDA For Advanced Renal Cell Carcinoma Apr 09 2015
Exelixis’ Cabozantinib Granted Fast Track Designation by FDA For Advanced Renal Cell Carcinoma Apr 09 2015
Roche open to alliances in hunt for cancer drug combinations Apr 01 2015
Roche open to alliances in hunt for cancer drug combinations Apr 01 2015
Cramer Remix: In all my years, never seen this! Mar 30 2015
3 (Rough) Dates Exelixis Shareholders Need to Know Mar 30 2015
Biotech in nice uptrend: Adami Mar 25 2015
Is Exelixis (EXEL) Stock a Solid Choice Right Now? - Tale of the Tape Mar 18 2015
EXELIXIS, INC. Financials Mar 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK